Press Releases
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 6, 2021-- Net Revenues Increased 550% Compared to 2020 Fourth Quarter --
-
Apr 22, 2021-- Conference Call Scheduled for 4:30 p.m. ET --
-
Apr 21, 2021Posters Focus on Perfect-Use Efficacy Data and Sexual Satisfaction and Function Among Women in the Phase 3 AMPOWER Trial
-
Mar 17, 2021- Over 2,400 Phexxi units dispensed in February 2021, up 30% from prior month -
-
Mar 4, 2021-- Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel prescriptions growing month over month, catalyzed by "Get Phexxi" Direct-to-Consumer (DTC) Campaign launched February 14th --
-
Feb 18, 2021-- Conference Call Scheduled for 4:30 p.m. ET --
-
Feb 16, 2021Marketing campaign includes the brand's first-ever commercial spot introducing women to a birth control that puts them in control of their body, their sex life, and their pregnancy prevention.
-
Feb 4, 2021Collaboration will provide resources about Phexxi® contraceptive vaginal gel to oncologists, pharmacists and associated healthcare providers
-
Jan 12, 2021Evofem honored amongst best companies globally for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi®
-
Dec 22, 2020Approximately 25 Million Adult Women Covered by Medicaid
-
Dec 17, 2020High Level of Interest from Clinical Sites Seeking to Participate in EVOGUARD Trial
-
Nov 9, 2020Launched Phexxi™ (lactic acid, citric acid, potassium bitartrate) in U.S. for Hormone-free Contraception
-
Oct 27, 2020-- Conference Call Scheduled for 5:00 p.m. ET --
-
Oct 26, 2020- Live moderated video webcast discussion with members of Evofem management and Key Opinion Leader Patty Cason, RN, MS, FNP-BC, on Thursday, October 29th at 2:00 p.m. ET -
-
Sep 14, 2020- Company plans to initiate Phase 3 STI trial by the end of 2020 -
-
Sep 8, 2020- A First-in-Class Vaginal pH Modulator Designed for Use "In-the-Moment" -
-
Aug 4, 2020- Advancing Precommercial Activities in Preparation for Phexxi™ Commercial Launch in September 2020 -
-
Jul 23, 2020-- Conference Call Scheduled for 11:00 a.m. EDT --
-
Jul 1, 2020- On-Track for September Launch of Phexxi™, the First FDA-Approved, Non-Hormonal, On-Demand Prescription Contraceptive Gel -
-
May 22, 2020- A New Class of Female-Controlled Birth Control for Use In-The-Moment -
-
May 6, 2020- On-Track for Phexxi™ PDUFA Date: May 25, 2020 -
-
Apr 28, 2020-- Conference Call Scheduled for 11:00 a.m. ET --
-
Apr 27, 2020- Funding to Support the Company's Launch and Commercialization Plans for Phexxi™ -
-
Apr 24, 2020- Perfect Use Efficacy Up to 93.3%; Exploratory Findings Demonstrate Increased Sexual Satisfaction and Vaginal Lubrication; Company Provides Updated Safety Outcomes -
-
Mar 12, 2020-- U.S. Food and Drug Administration (FDA) Grants Conditional Approval for New Brand Name - Phexxi™ --
-
Mar 3, 2020-- Conference Call Scheduled for 11:00 a.m. EDT --
-
Feb 26, 2020- Distinguished Career at the U.S. Food and Drug Administration in CDER and the Office of Women's Health; Significant Industry and Regulatory Expertise -
-
Dec 18, 2019- Assigns PDUFA Goal Date of May 25, 2020 -
-
Dec 2, 2019- AMPREVENCE Study Met Primary and Secondary Endpoints - a 50% Relative Risk Reduction in Chlamydia Infection and a 78% Relative Risk Reduction in Gonorrhea Infection Compared to Placebo -
-
Nov 26, 2019- Submission Supported by Phase 3 AMPOWER Data -
-
Nov 14, 2019- San Diego Business Journal Recognizes the City's Top 15 Female Business Leaders -
-
Nov 6, 2019Company on Track for Amphora NDA Resubmission to the U.S. FDA
-
Oct 24, 2019-- Conference Call Scheduled for 11:00 a.m. EST --
-
Aug 26, 2019-- Company on Track to Report Top-Line AMPREVENCE Results in November 2019 --
-
Aug 5, 2019Amphora NDA Resubmission Remains on Track for Q4 2019
-
Jul 30, 2019-- Conference Call Scheduled for 11:00 a.m. EDT --
-
Jul 1, 2019
-
Jun 10, 2019- Strategic financing to advance the commercialization of Evofem's lead asset, Amphora® -
-
May 7, 2019Management to Host Conference Call at 11:00 a.m. EDT
-
Apr 30, 2019-- Conference Call Scheduled for 11:00 a.m. EDT --
-
Apr 23, 2019Top-line Data Expected in the Fourth Quarter of 2019
-
Apr 11, 2019Financing to fund pre-launch commercialization activities of Amphora® (L-lactic acid, citric acid, and potassium bitartrate), a novel, investigational non-hormonal, on-demand, female contraceptive
-
Mar 1, 2019Positive Phase 3 Amphora Results Enabling NDA Submission
-
Feb 19, 2019-- Conference Call Scheduled for 11:00 a.m. EST --
-
Jan 3, 2019- Company to Resubmit New Drug Application (NDA) for Amphora as Hormone-free Birth Control in Q2 2019 Based on Positive Top-line Phase 3 Study Results -
-
Nov 8, 2018-- Company Remains on Track for AMPOWER Top-line Results in Late 2018 --
-
Nov 7, 2018Management to Host Conference Call at 11:00 a.m. EST
-
Nov 1, 2018- Currently 16.5M women in the U.S. are not using birth control and want to avoid pregnancy
-
Oct 24, 2018-- Conference Call Scheduled for 11:00 a.m. EST --
-
Sep 26, 2018-- On World Contraception Day, these U.S statistics support the continued need for new woman-controlled, non-hormonal birth control innovations. Ideally such methods would protect against pregnancy and also have other preventive indications (such as STI prevention), thus giving women better control over their sexual and reproductive health.
-
Aug 2, 2018Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data now expected in Late 2018
-
Jul 19, 2018-- Conference Call Scheduled for 11:00 a.m. EDT --